Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets

作者全名："Guo, Aiyuan; Zhang, Jingwei; Tian, Yuqiu; Peng, Yun; Luo, Peng; Zhang, Jian; Liu, Zaoqu; Wu, Wantao; Zhang, Hao; Cheng, Quan"

作者地址："[Guo, Aiyuan] Cent South Univ, Xiangya Hosp 3, Dept Dermatol, Changsha, Peoples R China; [Zhang, Jingwei; Peng, Yun; Cheng, Quan] Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China; [Zhang, Jingwei; Cheng, Quan] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China; [Tian, Yuqiu] Zhuzhou Cent Hosp, Dept Infect Dis, Zhuzhou, Peoples R China; [Peng, Yun] Cent South Univ, Xiangya Hosp, Teaching & Res Sect Clin Nursing, Changsha, Peoples R China; [Luo, Peng; Zhang, Jian] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China; [Liu, Zaoqu] Zhengzhou Univ, Affiliated Hosp 1, Dept Intervent Radiol, Zhengzhou, Peoples R China; [Wu, Wantao] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Peoples R China; [Zhang, Hao] Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, Chongqing, Peoples R China; [Cheng, Quan] Cent South Univ, Xiangya Hosp, Clin Diag & Therapy Ctr Glioma, Changsha, Peoples R China"

通信作者："Cheng, Q (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China.; Cheng, Q (通讯作者)，Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China.; Zhang, H (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, Chongqing, Peoples R China.; Cheng, Q (通讯作者)，Cent South Univ, Xiangya Hosp, Clin Diag & Therapy Ctr Glioma, Changsha, Peoples R China."

来源：FRONTIERS IN IMMUNOLOGY

ESI学科分类：IMMUNOLOGY

WOS号：WOS:000882749200001

JCR分区：Q1

影响因子：7.3

年份：2022

卷号：13

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：CD93; pan-cancer; immunotherapy; macrophages; T cells; tumor microenvironment

摘要："CD93 is a transmembrane receptor that is mainly expressed on endothelial cells. A recent study found that upregulated CD93 in tumor vessels is essential for tumor angiogenesis in several cancers. However, the underlying mechanisms are largely unexplored. Our present research systematically analyzed the characteristics of CD93 in tumor immunotherapy among 33 cancers. CD93 levels and co-expression of CD93 on cancer and stromal cells were detected using public databases and multiple immunofluorescence staining. The Kaplan-Meier (KM) analysis identified the predictive role of CD93 in these cancer types. The survival differences between CD93 mutants and WT, CNV groups, and methylation were also investigated. The immune landscape of CD93 in the tumor microenvironment was analyzed using the SangerBox, TIMER 2.0, and single-cell sequencing. The immunotherapy value of CD93 was predicted through public databases. CD93 mRNA and protein levels differed significantly between cancer samples and adjacent control tissues in multiply cancer types. CD93 mRNA expression associated with patient prognosis in many cancers. The correlation of CD93 levels with mutational status of other gene in these cancers was also analyzed. CD93 levels significantly positively related to three scores (immune, stromal, and extimate), immune infiltrates, immune checkpoints, and neoantigen expression.. Additionally, single-cell sequencing revealed that CD93 is predominantly co-expressed on tumor and stromal cells, such as endothelial cells, cancer-associated fibroblasts (CAFs), neutrophils, T cells, macrophages, M1 and M2 macrophages. Several immune-related signaling pathways were enriched based on CD93 expression, including immune cells activation and migration, focal adhesion, leukocyte transendothelial migration, oxidative phosphorylation, and complement. Multiple immunofluorescence staining displayed the relationship between CD93 expression and CD8, CD68, and CD163 in these cancers. Finally, the treatment response of CD93 in many immunotherapy cohorts and sensitive small molecules was predicted from the public datasets. CD93 expression is closely associated with clinical prognosis and immune infiltrates in a variety of tumors. Targeting CD93-related signaling pathways in the tumor microenvironment may be a novel therapeutic strategy for tumor immunotherapy."

基金机构：Hunan Provincial Health Committee Foundation of China; Hunan Provincial Natural Science Foundation of China; [202204044869]; [2020JJ5850]

基金资助正文："Funding This work was supported by the Hunan Provincial Health Committee Foundation of China (NO.202204044869), Hunan Provincial Natural Science Foundation of China (NO.2020JJ5850)."